Thrombophilias, which are associated with a predisposition to thrombotic events,
have been implicated in adverse obstetric outcomes such as intrauterine growth
restriction and pre-eclampsia. Heparin administration in pregnancy may reduce
the risk of these events.
Key messages
􀃎 There is no evidence from randomized controlled trials to determine whether
or not heparin decrease the incidence of stillbirth, intrauterine growth
restriction, placental abruption and pre-eclampsia in women with
thrombophilia.
􀃎 Further studies are required to evaluate the effect of heparin on pregnancy
outcomes for women with thrombophilia.